Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases

Mölndal, Sweden, Kunshan, China and Ingelheim, Germany – 3 January 2024 Suzhou Ribo Life Science Co. Ltd. and Ribocure Pharmaceuticals AB (Ribo) today announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH). The partnership brings together Ribo’s leading experience in the discovery and clinical development of small […]